Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Read responses to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harrison, C M
Right arrow Articles by Andersen, C C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harrison, C M
Right arrow Articles by Andersen, C C
Archives of Disease in Childhood Fetal and Neonatal Edition 2005;90:F6-F10
© 2005 Archives of Disease in Childhood Fetal and Neonatal Edition


REVIEW

Exhaled breath measures of inflammation: are they useful in neonatal chronic lung disease?

C M Harrison, C C Andersen

Department of Paediatrics, Mercy Hospital for Women, Melbourne, Australia

Correspondence to:
Correspondence to:
Dr Andersen
Department of Paediatrics, Mercy Hospital for Women, Clarendon St, East Melbourne, Victoria 3002, Australia; candersen{at}mercy.com.au


ABSTRACT
Neonatal chronic lung disease is a common problem for surviving infants of extreme prematurity. Although the precise pathophysiology is still not known, it is clear that inflammation provides a common link that amplifies the injury to the premature lung. Current invasive measures of pulmonary inflammation include markers in blood and airway effluent, with the cellular composition of tracheal fluid being the "gold standard". In this article available exhaled breath measures, particularly nitric oxide, carbon monoxide, volatile hydrocarbons, and exhaled breath condensate, are reviewed with particular reference to sample collection, analysis, and common pitfalls as they apply to the ventilated premature newborn at risk of chronic lung disease. Although they have great potential, all measures require thorough validation before being used clinically.


Abbreviations: CLD, chronic lung disease; eNO, exhaled nitric oxide; eCO, exhaled carbon monoxide; EBC, exhaled breath condensate

Keywords: chronic lung disease; inflammation; preterm; breath hydrocarbons; nitric oxide; carbon monoxide




This article has been cited by other articles:


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
F-C Cheah, B A Darlow, and C C Winterbourn
Association of hydrogen peroxide in exhaled breath condensates from infants with respiratory distress syndrome with the development of chronic lung disease.
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2006; 91(2): F155 - F155.
[Full Text] [PDF]


Home page
Eur Respir JHome page
I. Horvath, J. Hunt, P. J. Barnes, and On behalf of the ATS/ERS Task Force on Exhaled Bre
Exhaled breath condensate: methodological recommendations and unresolved questions
Eur. Respir. J., September 1, 2005; 26(3): 523 - 548.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Hydrogen peroxide in exhaled breath condensates from infants with RDS and the development of CLD
Fook-Choe Cheah, et al.
Fetal Neonatal Ed. Online, 4 Jul 2005 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health